Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 363, Suchdauer: 0.96s

12 3 4 5 6 7 8 9 10 11 weiter »

1
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial

von Cook, JA ; Patten, PEM ; Peckham, N ; et al.
- View full text via BASE
Merkliste

2
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

von Kelly, E. ; Greenland, M. ; de Whalley, P. ; et al.

In Journal of Infection January 2026 92(1)
- View full text via DOI
Merkliste

3
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)

von Aley, Robert ; Anslow, Rachel ; Cathie, Katrina ; et al.

In Vaccine 30 August 2025 62
- View full text via DOI
Merkliste

4
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study

von Feng, Shuo ; Bibi, Sagida ; Aley, Parvinder K. ; et al.

In Journal of Infection February 2025 90(2)
- View full text via DOI
Merkliste

5
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial

von Bennett, Chijioke ; Chau, Gordon ; Clayton, Erika ; et al.

In Journal of Infection February 2025 90(2)
- View full text via DOI
Merkliste

6
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

von Anderson, Anna ; Ang, Mary ; Barnes, Timothy ; et al.

In The Lancet Infectious Diseases June 2024 24(6):581-593
- View full text via DOI
Merkliste

7
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

von Shaw, Robert H. ; Greenland, Melanie ; Stuart, Arabella S.V. ; et al.

In Journal of Infection June 2023 86(6):574-583
- View full text via DOI
Merkliste

8
Author Correction: Calcium-permeable channelrhodopsins for the photocontrol of calcium signalling

von Fernandez Lahore, Rodrigo G. ; Pampaloni, Niccolò P. ; Schiewer, Enrico ; et al.

Nature Communications. 15(1)
- Zum Volltext in PubMed Central
Merkliste

9
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol

von Brito-Mutunayagam, S ; Hamilton, DO ; Mitsi, E ; et al.
- View full text via BASE
Merkliste

10
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

von Vivek Shinde ; Anthonet Lombard Koen ; Zaheer Hoosain ; et al.

Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)

Schlagworte: Novavax, Inc.; the Bill & Melinda Gates Foundation; and the Coalition for Epidemic Preparedness Innovations; Immunologic diseases. Allergy; RC581-607; Therapeutics. Pharmacology; RM1-950
- View full text via DOI
Merkliste

11
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

von Kelly, Eimear ; Greenland, Melanie ; de Whalley, Philip C.S. ; et al.

In Journal of Infection September 2023 87(3):230-241
- View full text via DOI
Merkliste

12
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

von Munro, Alasdair P.S. ; Bartholomew, Jazz ; Presland, Laura ; et al.

In The Lancet Respiratory Medicine November 2022 10(11):1049-1060
- View full text via DOI
Merkliste

13
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

von Marchevsky, Natalie Gabrielle ; Li, Grace ; Aley, Parvinder ; et al.

In eBioMedicine July 2022 81
- View full text via DOI
Merkliste

14
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

von Madhi, Shabir A ; Moodley, Dhayendre ; Hanley, Sherika ; et al.

In The Lancet HIV May 2022 9(5):e309-e322
- View full text via DOI
Merkliste

15
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

von Kanitkar, Shubhangi A. ; Kakrani, Arjun L. ; Tripathy, Srikanth P. ; et al.

In The Lancet Regional Health - Southeast Asia March 2023 10
- View full text via DOI
Merkliste

16
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

von Watson, Marion E.E. ; Song, Rinn ; Cicconi, Paola ; et al.

In The Lancet HIV August 2021 8(8):e474-e485
- View full text via DOI
Merkliste

17
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

von Emary, Katherine R W ; Golubchik, Tanya ; Aley, Parvinder K ; et al.

In The Lancet 10-16 April 2021 397(10282):1351-1362
- View full text via DOI
Merkliste

18
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

von Aban, Marites ; Abeyskera, Kushala W.M. ; Aboagye, Jeremy ; et al.

In The Lancet 6-12 March 2021 397(10277):881-891
- View full text via DOI
Merkliste

19
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

von Aban, Marites ; Abayomi, Fatola ; Abeyskera, Kushala ; et al.

In The Lancet 9-15 January 2021 397(10269):99-111
- View full text via DOI
Merkliste

20
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

von Soiza, Roy L. ; Brittain-Long, Robin ; Scicluna, Chiara ; et al.

In The Lancet Respiratory Medicine February 2022 10(2):167-179
- View full text via DOI
Merkliste

21
Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C

von Tiley, KS ; Ratcliffe, H ; Voysey, M ; et al.
- View full text via BASE
Merkliste

22
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

von Aboagye, Jeremy ; Adams, Kelly ; Ali, Aabidah ; et al.

In The Lancet 19 December 2020-1 January 2021 396(10267):1979-1993
- View full text via DOI
Merkliste

23
Calcium-permeable channelrhodopsins for the photocontrol of calcium signalling

von Rodrigo G. Fernandez Lahore ; Niccolò P. Pampaloni ; Enrico Schiewer ; et al.

Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)

Schlagworte: Science
- View full text via DOI
Merkliste

24
Calcium-permeable channelrhodopsins for the photocontrol of calcium signalling

von Fernandez Lahore, Rodrigo G. ; Pampaloni, Niccolò Paolo ; Schiewer, Enrico ; et al.

Fernandez Lahore, Rodrigo G., Pampaloni, Niccolò Paolo, Schiewer, Enrico, Heim, M.-Marcel, Tillert, Linda, Vierock, Johannes, Oppermann, Johannes, Walther, Jakob, Schmitz, Dietmar, Owald, David, Plested, Andrew, Rost, Benjamin, Hegemann, Peter: Calcium-permeable channelrhodopsins for the photocontrol of calcium signalling, Berlin: Humboldt-Universität zu Berlin 2024.

Schlagworte: Naturwissenschaften
- View full text via BASE
Merkliste

25
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

von Ratcliffe, H ; Tiley, K ; Longet, S ; et al.
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag